|Assessment Status||Rapid Review complete|
|Indication||Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.|
|Rapid review commissioned||11/05/2017|
|Rapid review completed||14/06/2017|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
|Full pharmacoeconomic assessment commissioned by HSE||14/06/2017|
The company do not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.